Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patient with a tested JAK2 mutation: A case report and review literature  by Macías, Isabel
M
t
a
I
D
a
A
R
R
A
A
K
P
T
J
U
P
C
1
t
h
t
h
a
i
g
a
e
o
a
o
s
m
K
p
m
p
h
2
cCASE  REPORT  –  OPEN  ACCESS
International Journal of Surgery Case Reports 28 (2016) 93–96
Contents lists available at ScienceDirect
International  Journal  of  Surgery  Case  Reports
journa l h omepage: www.caserepor ts .com
assive  upper  gastrointestinal  bleeding  due  to  splenoportal  axis
hrombosis  in  a  patient  with  a  tested  JAK2  mutation:  A  case  report
nd  review  literature
sabel  Macías  (PhD)
epartment of Surgery, Universitary Hospital Reina Soﬁa, Córdoba, Spain
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 8 June 2016
eceived in revised form 8 August 2016
ccepted 8 August 2016
vailable online 13 August 2016
a  b  s  t  r  a  c  t
Portal  hypertension  is  a  clinical  syndrome  deﬁned  as a portal  venous  pressure  that  exceeds  10  mmHg.
Cirrhosis  is  the most  common  cause  of  portal  hypertension  and thrombosis  of  the  splenoportal  axis  not
associated  with  liver  cirrhosis  is the second  cause  of  portal  hypertension  in the  Western  world.  The
primary  myeloproliferative  disorders  are  the  main  cause  of portal  venous  thrombosis  and somatic  muta-
tion  of Janus  Kinase  2 gene  (JAK2 V617F)  can  be  found  in  approximately  90%  of polycythemia  vera,  50%
of  essential  thrombocyrosis  and  50%  primary  myeloﬁbrosis.  A  a  55-year-old  man  with  JAK2  mutation-eywords:
ortal hypertension
hrombosis portal
AK2
pper bleeding
rimary myeloproliferative disorders
associated  splenoportal  axis  hypertension  and  bleeding  complications  due  to oesophageal  varices  is
reported.  A massive  upper  bleeding  episode  made  an emergent  surgery  to be done  immediatelly  at
seventh  day.  The  patient  was  discharged  home  at  ﬁfteenth  day  after  surgery.
©  2016  The  Author.  Published  by  Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is  an open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).ase report
. Introduction
Portal hypertension is a clinical syndrome deﬁned as a por-
al venous pressure that exceeds 10 mmHg. The etiology of portal
ypertension can be classiﬁed as prehepatic, intrahepatic, or pos-
hepatic (Table 1) [1]. Cirrhosis is the most common cause of portal
ypertension and thrombosis of the splenoportal axis not associ-
ted with liver cirrhosis is the second cause of portal hypertension
n the Western world [2]. There are identiﬁed systemics thrombo-
enic factors in 60% of cases and there are several etiologic factors
ssociated in 15% of them [3].
The primary myeloproliferative disorders (polycythemia vera,
ssential thrombocytosis and primary myeloﬁbrosis) are clonal dis-
rders arising in a pluripotent hematopoietic stem cell, that causes
n unregulated increase in the number of erythrocytes, leukocytes
r platelets [4]. They are the main cause of portal venous thrombo-
is, although changes in blood in a portal hypertension context can
ake the diagnosis more difﬁcult [5]. Somatic mutation of Janus
inase 2 gene (JAK2 V617F) can be found in approximately 90% of
olycythemia vera, 50% of essential thrombocytosis and 50% pri-
ary myeloﬁbrosis [4] (Table 2).
The high incidence of gastrointestinal bleeding in patients with
ortal vein thrombosis and the association between oesophageal
E-mail address: maciaspuerta@gmail.com
ttp://dx.doi.org/10.1016/j.ijscr.2016.08.013
210-2612/© 2016 The Author. Published by Elsevier Ltd on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/).varices and JAK2-related splanchnic vein thromboses should be
kept in mind when managing such patients [6].
2. Case report
We present a 55-year-old man  with JAK2 mutation-associated
splenoportal axis hypertension, splenomegaly and bleeding com-
plications due to oesophageal varices. He’s on oral anticoagulants
therapy. He had history of cholecystectomy 9 years ago. This patient
was referred to our tertiary hospital for evaluation of long dura-
tion abdominal pain and hematochezia. He was admitted in the
gastrointestinal bleeding unit.
An early endoscopy was performed within 24 h of presentation:
stomach fundus was  ﬁlled with blood clots and there were some
isolated fundal gastric varices. (Fig. 1). Blood test revealed leuko-
cytosis (26.000 leukocytos per mm3) and thrombocytosis (767.000
thrombocytes per mm3).
A computed tomography angiography (CTA) under ﬂuoroscopic
guidance was performed. The procedure was  carried out under
sedation and local anesthesia. Celiac trunk, splenic artery and upper
mesenteric artery were catheterized with a 5 French (Fr) catheter.
After vasodilators agents administration, intraoperative control
arteriography showed absence of portal and splenic opaciﬁcation,
which supports thrombosis in splenoportal axis (Fig. 2).
The patient had a massive upper bleeding episode at seventh
day, with tachycardia, tachypnoea, cool clammy skin, hypoten-
sion and confusión and the use of luminal tamponade with
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Table 1
Causes of portal hypertension [1].
ETIOLOGY OF PORTAL HYPERTENSION BY LOCATION
PREHEPATIC INTRAHEPATIC POSTHEPATIC
Portal vein thrombosis Cirrhosis Budd-Chiari syndrome
Splenic vein thrombosis Primary biliary cirrhosis Congestive heart failure
Congenital thrombosis of portal vein Inﬁltrative liver disease Constritive pericarditis
Arteriovenous ﬁstula Idiopatic portal hypertension Tricuspid valve diseases
Congenital hepatic ﬁbrosis
Policystic liver disease
Postsinusoidal venooclusive disease
Fig. 1. Early endoscopy shows isolated fundal gastric varices (dark arrow).
Table 2
Representative molecular defects in the chronic myeloproliferative disorders [4].
CHRONIC MYELOPROLIFERATIVE DISORDERS
DISEASE MOLECULAR DEFECT
Chronic myelogenous leukemia BCR-ABL
Chronic eosinophilic leukemia FIP1L1-PDGFRA
Chronic neutrophilic leukemia BCR-ABL p230
Chronic myelomonocytic leukemia TEL-PDGFRB
Systemic mastocytosis KIT D8116V
Polycythemia vera JAK2 V617F (≈90% positive)
Essential thrombocytosis JAK2 V617F (≈50% positive)
MLP  W515L/K (≈3% positive)
MLP  K39N
S
a
p
Fig. 2. Angiography under CT guidance. Absence of portal and splenic opaciﬁcation
(thombosis).
Abbreviation: CT, computed tomography.
T
CPrimary myeloﬁbrosis JAK2 V617F (≈50%)
MLP W515L/K (≈14%)engstaken-Blakemore was  a life-saving maneuver. Unfortunately,
cute bleeding was uncontrolled so an emergent surgery was
erformed inmediatelly. Transjugular intrahepatic portosystemic
able 3
ontraindications for TIPS [7].
Contraindications for Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Absolute contraindications Relative contr
Severe elevate right heart pressure Complete hep
Severe pulmonary hypertension Complete por
Severe congestive heart failure Hepatocellula
Severe encephalopathy Severe coagul
Uncorrectable bleeding diathesis Severe thromb
Active  systemic or hepatic bacterial infection Advanced live
Unrelieved biliary obstruction Moderate pulmshunt (TIPS) is contraindicated because of portal vein thrombosis
[7] (see Table 3).
A midline laparotomy was  performed: a great stomach ﬁlled
with blood and blood clots takes up most of left upper cuadrant.
Some fundal gastric varices are due to thrombosis in splenopor-
tal axis. Neither esophageal nor other gastric varices were seen.
A splenectomy was performed ﬁrst, providing better exposure for
gastric devascularization (Figs. 3 and 4 ). Acute upper bleeding was
successfully controlled and a Sugiura procedure was not required.
The patient was discharged home ﬁfteen days after surgery.
Pathologic analysis did not reveal nothing but splenomegaly. Essen-
tial thrombocyrosis was  diagnosed and he is currently receiving
follow-up care by haematologist. No other bleeding episodes were
reported.aindications
atic vein obstruction
tal vein thrombosis
r carcinoma
opathy (INR greater than 5)
ocytopenia (platelet count less than 20,000/cm3)
r dysfunction (bilirubin greater than 5 mg/dL or MELD greater than 17)
onary hypertension
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limited to these situations in which endoscopy and medical mea-igs. 3 and 4. Images from surgery. Fundal gastric varices are ligated (arrow); spec-
men from splenectomy (splenomegaly).
. Discussion
The surgery of portal hypertension has been currently aban-
oned because of adoption of new procedures as TIPS. The
ransjugular intrahepatic portacaval shunt is an interventional
adiologic procedure employed as a useful treatment for the symp-
oms of portal hypertension since early 1970s by which a tractPEN  ACCESS
ry Case Reports 28 (2016) 93–96 95
is created between the hepatic and portal vein and reduces por-
tal pressure. TIPS alleviates severe symptoms related to portal
hypertension and can be a life-saving procedure in emergent
upper gastrointestinal bleeding, if bleeding is uncontrolled with
resuscitation, medical measures, endoscopic therapies and balloon
tamponade [17].
Maintaining gastric pH above 6 optimises platelet aggregation
and clot formation.
Although there is evidence of improved clinical outcome asso-
ciated with post-endoscopic pharmacological management of
patients at high risk of rebleeding, there is a lack of evidence to
support pre-endoscopic treatment with proton pump inhibitors
[8,9].
Endoscopy is an effective intervention for acute gastrointestinal
bleeding and plays a critical role in the diagnosis and therapy in
variceal hemorrhage. Current clinical practice involves endoscopy
being undertaken in working hours within 24 h of presentation.
Optimum resuscitation is essential before endoscopy in order to
reduce the potential cardiorespiratory complications of the proce-
dure [10,11].
Medical treatment includes the use of vasoactive drugs, which
exert their action by reducing portal pressure and variceal pressure.
Whenever a variceal bleeding is suspected, vasoactive drugs should
be started as soon as possible. Literature shows that early admin-
istration of these drugs reduces the rate of active bleeding during
endoscopy. The optimal duration of medical therapy is not well
established. Current guidelines recommend maintaining vasoac-
tive treatment for 2–5 days (period in which rebleeding is more
frequent). Current data does not show superiority of any drugs, so
the choice is based on hospital resources.
There are many vasoactive drugs to treat hemorrhage by
decreasing blood ﬂow. Published data does not permit ﬁrm con-
clusions about the superiority of any of them. Terlipressin is a
synthetic analogue of vasopressin with few side effects. Its utility
is base on reducing portal pressure and its effects are still signiﬁ-
cant four hours after administration. Terlipressin controls variceal
bleeding at 48 h in 80% of cases, and has been shown to improve sur-
vival when compared to placebo. Terlipressin is limited by systemic
vasoconstrictive properties that can produce ischemic complica-
tions and dysrhythmias. It should be used with caution and avoided
in those patients with a history of ischemic heart, cerebral dis-
ease, vascular disease or heart rhythm disorders [12]. Octreotide, a
somatostatin analog with a longer half-life, is a splanchnic vasocon-
strictor and inhibitor of glucagon and other vasodilatory peptides.
It inhibits acid and pepsin secretion, so reduces gastroduode-
nal mucosal blood ﬂow. Published data does not show improved
surveillance [14].
The surgical treatment in portal hypertension has as target
to avoid rebleeding keeping liver function preserved, without
encephalopathy. It has been proposed many techniques and there
are two  with more acceptance: distal splenorenal shunt (Warren
procedure) and esophagogastric devascularization and splenec-
tomy [15,16]. The use of beta- blockers and endoscopy must be
considerated as secondary prophylaxis of variceal haemorrhage:
when acute bleeding is successfully controlled, the recurrence of
rebleeding can be as high as 50% within the ﬁrst day of ﬁrst episode.
4. Conclusion
Emergent surgery in a portal hypertension context has beensures are not sufﬁcient enough to control bleeding and TIPS are
contraindicated. Nowadays, these emergent situations are only iso-
lated cases.
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